What Are the New Guidelines for Prescribing Opioids in Australia?
Understanding current TGA, SIRA, and prescriber guidelines that affect your claims management decisions.
Published: 4 April 2026
Introduction
Opioid prescribing guidelines in Australia have shifted significantly over the past 5 years. As an insurance claims manager, understanding these changes is essential to recognizing when treatment aligns with current best practice and when it deviates from recommended standards.
The Therapeutic Goods Administration (TGA), State Insurance Regulatory Authorities (SIRA), WorkSafe, and professional bodies like the Faculty of Pain Medicine have all issued updated guidance that emphasizes structured risk assessment, conservative dosing, regular monitoring, and alternative therapies. These guidelines inform what you should expect to see in medical documentation and provide your rationale for challenging non-compliant prescribing patterns.
Key Guideline Changes in Recent Years
TGA Position on Long-Term Opioid Therapy
The Therapeutic Goods Administration has become increasingly cautious about long-term opioid use. Key TGA positions include:
- Limited evidence for long-term use: The TGA has emphasized that evidence supporting opioid efficacy in chronic non-cancer pain beyond 12 weeks is limited. While some patients benefit from long-term opioid therapy, the evidence base is weaker than for acute or cancer-related pain.
- Risk-benefit assessment required: Each opioid prescription should be based on explicit risk-benefit analysis. As a claims manager, you should see documented evidence that this assessment has occurred before opioids are initiated or continued long-term.
- Preference for non-opioid alternatives: The TGA supports moving toward non-opioid pain management strategies, including multimodal approaches combining physical therapy, psychological interventions, and other medications.
- Minimum effective dose: The TGA recommends starting at low doses and titrating slowly. Rapid dose escalation is flagged as departing from best practice.
SIRA and State-Based Worker Compensation Guidance
The State Insurance Regulatory Authority (SIRA) in New South Wales and equivalent bodies in other states have issued worker compensation-specific opioid management guidelines. Key elements include:
- Medical Certificate requirements: For workers compensation claims, particular opioid products and doses may require specific medical certification or approval pathways.
- Multidisciplinary assessment: SIRA guidance emphasizes that opioid therapy should be part of a coordinated pain management plan that includes physical therapy, occupational therapy, and psychological support where indicated.
- Real-time prescription monitoring: SafeScript (in Victoria and other participating states) and state-based monitoring systems are now expected to be used by prescribers to detect multiple-prescriber presentations and other aberrant patterns.
- Regular medical review: Workers compensation claims involving opioids should include structured medical review at regular intervals, with clear documentation of ongoing clinical justification.
Faculty of Pain Medicine Recommendations
The Faculty of Pain Medicine of the Australian and New Zealand College of Anaesthetists provides professional guidance on opioid prescribing. Their key recommendations include:
- Structured patient selection and comprehensive pain history before initiating opioids
- Documented informed consent discussing risks, benefits, and alternatives
- Written opioid treatment agreements setting expectations for medication use
- Baseline assessment including pain, function, mental health, and substance use risk
- Regular monitoring using standardized outcome measures
- Consideration of dose reduction or cessation if benefits are not maintained or if harms increase
PBS Authority Requirements for Opioids
Australia's Pharmaceutical Benefits Scheme (PBS) has implemented restricted access for some opioid products. As a claims manager, understanding PBS authority requirements helps you identify when prescribing is following official pharmaceutical pathways.
| Opioid Product / Scenario | PBS Authority Status | What This Means for Claims |
|---|---|---|
| Controlled-release opioids (e.g., modified-release morphine, oxycodone) | Restricted; requires specialist authority or GP with demonstrated experience | If your claimant is receiving these, confirm the prescriber has appropriate authority. Prescribing outside authority pathways may indicate non-compliance with PBS rules. |
| Opioids for cancer pain | Generally unrestricted once diagnosis confirmed | Cancer-related pain has different guideline frameworks. Ensure documentation clearly indicates cancer-related diagnosis if higher doses are prescribed. |
| Opioids for chronic non-cancer pain (workers compensation, CTP, NDIS) | Increasingly restricted; may require specialist review or SIRA approval | For ongoing opioid use beyond 12 weeks, look for evidence of specialist involvement or approved pathway documentation. Lack of such documentation may indicate off-pathway prescribing. |
| Patch-based opioids (e.g., fentanyl patches) | Restricted; typically for opioid-experienced patients or cancer pain | Patches should only be prescribed if the claimant is already taking regular opioids or has cancer-related pain. Patches in opioid-naive patients is a significant red flag. |
SafeScript and Real-Time Prescription Monitoring
SafeScript in Victoria and QScript in Queensland (now being harmonized nationally) are real-time prescription monitoring systems that track Schedule 8 (controlled) medications, including opioids. As a claims manager, you should understand what these systems reveal.
How RTPM Affects Your Claims
Real-time prescription monitoring (RTPM) systems flag:
- Multiple prescriber presentations: When a patient fills prescriptions from more than one doctor within a short timeframe, flagging potential doctor shopping.
- Early refills or overlapping supplies: When medications are dispensed before the previous supply should be exhausted.
- Unusual dosing patterns: Significant dose increases or unusual drug combinations.
- Concurrent benzodiazepine or sedating drug use: Which increases overdose risk and is commonly monitored.
What's Expected in Current Prescribing
Current guidelines expect that prescribers routinely check RTPM systems before initiating opioid therapy and at regular intervals during therapy. Documentation should include evidence that these checks have occurred, particularly if multiple providers are involved in the claimant's care or if the patient presents with medication-seeking concerns.
Dosing Guidelines and Maximum Daily Dose Recommendations
Recent guidelines have become more conservative regarding maximum daily doses. The Faculty of Pain Medicine and international best practice recommend careful consideration before exceeding certain thresholds.
| Dose Level | Current Guideline Position | Claims Manager Consideration |
|---|---|---|
| 0-20 mg morphine equivalent daily (MED) | Low-dose range; appropriate for initiation and maintenance in many cases | No specific concerns. Monitor for effectiveness and side effects. |
| 21-50 mg MED | Moderate dose; consider review if patient not improving | Appropriate for established therapy with documented benefit. Rapid escalation through this range warrants questioning. |
| 51-90 mg MED | Higher dose; generally not recommended unless specialist-supervised with clear ongoing benefit | Request specialist involvement and documented risk-benefit assessment. Absence of specialist oversight is a red flag. |
| Above 90 mg MED | Very high dose; strong recommendation for specialist pain medicine involvement; increased risk of overdose and opioid-related harm | Requires specialist documentation of ongoing clinical indication and risk mitigation. High-dose therapy without specialist involvement is inconsistent with current guidelines. |
Informed Consent and Treatment Agreement Requirements
Current guidelines place significant emphasis on informed consent and documented treatment agreements before opioid therapy begins. As a claims manager, you should expect to see these in the medical record.
Documentation You Should See Before Opioid Initiation
- Documented discussion of opioid risks, including addiction potential, overdose risk, side effects, and driving safety
- Discussion of alternative pain management options and why opioids are being chosen despite these risks
- Written opioid treatment agreement or contract setting expectations for medication use, including restrictions on dose changes without consultation, requirements for monitoring, and consequences of non-compliance
- Confirmation that the patient understands the risks and agrees to the treatment plan
- Documentation that the patient has been counseled on not sharing medications, safe storage, and overdose risk, particularly if benzodiazepines are concurrent
If you're seeing opioid prescriptions without evidence of these consent discussions and agreements, this represents non-compliance with current best practice guidelines.
Multimodal Pain Management as Guideline Standard
A key shift in recent guidelines is the expectation that opioid therapy is not used in isolation. Instead, opioids are one component of a multimodal pain management approach that might include:
- Physical therapy and exercise programs
- Psychological approaches such as cognitive behavioural therapy or acceptance and commitment therapy
- Other medications such as anticonvulsants, antidepressants, topical analgesics, or NSAIDs where appropriate
- Interventional procedures such as injections or spinal cord stimulation where indicated
- Occupational therapy and functional restoration programs
When reviewing opioid therapy in your claims, look for evidence that these complementary approaches are being offered or recommended. If your claimant is receiving opioids in isolation without referral to physiotherapy, psychology, or other modalities, the treatment approach may not be consistent with current guidelines.
What This Means for Your Claims: Practical Applications
Challenging Non-Compliant Prescribing
When you identify prescribing patterns that deviate from current guidelines (for example, high-dose opioids without specialist oversight, doses escalated without documented benefit, absence of monitoring documentation), you can now reference specific guidelines when requesting change. This language is more effective than subjective concerns.
Approving Guideline-Compliant Treatment
Conversely, when you see treatment that aligns with current guidelines (structured patient selection, documented informed consent, regular monitoring against the 5 A's, multimodal approach, appropriate specialist involvement), you can approve this treatment with confidence that it reflects best practice.
Using RTPM Data
Request SafeScript or QScript reports regularly for claimants on long-term opioids. These objective data sources help you identify aberrant behaviour patterns that might not be apparent from clinical notes alone.
Need expert guidance on whether your claimant's opioid therapy aligns with current guidelines?
IMM pharmacists provide independent medication reviews that assess opioid prescribing against TGA, SIRA, and Faculty of Pain Medicine standards. We help you identify treatment gaps and support your decision-making with evidence-based recommendations.
Learn About IMM's Medication Review ServicesConclusion
Australia's opioid prescribing guidelines have evolved toward more conservative, evidence-based approaches. These guidelines emphasize structured patient selection, informed consent, regular monitoring, and multimodal treatment. By understanding the current guideline landscape, you're better equipped to assess whether treatment in your claims aligns with best practice and to make informed decisions about treatment modification or specialist referral.
The regulatory environment around opioid prescribing continues to evolve, with increasing oversight through systems like SafeScript and increasing requirements for specialist involvement in high-dose or long-term therapy. Staying current with these guidelines strengthens your claims management and supports better outcomes for your claimants.
